Is it safe?
Can RCUS take a bad year?
Arcus Biosciences, Inc. holds $601M more cash than debt, and is burning $119M a quarter, about 1.5 years of cover.
$601M
Net cash
- Net debt / EBITDA
- net cash
Net debt / EBITDA · no net borrowings to measure against earnings
- Altman Z-score
- 2.58
Altman Z-score · grey zone, between 1.8 and 3
- Cash runway
- 1.5 years
Cash runway · burning $119M a quarter at the current rate
Details›
- Total debtQ2 2026
- $101M
- Cash and short-term investments
- $702M
- Net cash
- $601M
- EBITDA, trailing twelve months
- −$476M
- Operating profit, trailing twelve months
- −$486M
- Debt / equity
- 0.22×
- Annualised volatilitytwo years of daily moves
- 62%
- Worst drawdown on file
- −86%
- Below its 52-week high
- −2.6%
Balance sheet from SEC filings; drawdown and volatility from end-of-day closes; Altman Z from the filed statements.